Figures in cells are number of patients to be included per group, at α (2-tailed) = 0.05 and 1−β = 0.80, for different levels (30, 40, 50%) of expected change difference between groups on annual rate
The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the saf
The purpose of this study is to assess the long-term safety and efficacy of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP). In a subset of participants at participating sites, partici
